ArticleAAPS PharmSciTech2026
Development of Carboxymethyl Cellulose-Gelatin Aerogels for Urea Delivery.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Urea is an effective therapeutic agent for the treatment of chronic hyponatremia; however, its high water solubility leads to rapid dissolution, limiting sustained therapeutic efficacy and patient compliance. This study aimed to develop and evaluate controlled-release urea delivery systems using biopolymer-based aerogel and xerogel matrices. Urea-loaded aerogel and xerogel composites were prepared from carboxymethyl cellulose (CMC) and surplus gelatin (GE), crosslinked with varying concentrations of glutaraldehyde (GA). The effects of the CMC:GE ratio and GA concentration on gelation behavior, swelling properties, and urea release kinetics were systematically investigated. Structural and thermal characteristics were analyzed using scanning electron microscopy (SEM), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). The CMC:GE ratio significantly influenced the structural and functional properties of the composites. Among the formulations studied, the aerogel with a CMC:GE ratio of 1:3 and 5% (v/v) GA xhibited the most effective controlled-release performance, providing a markedly prolonged urea release compared with the corresponding xerogel. XRD and DSC analyses indicated that urea was predominantly present in an amorphous or molecularly dispersed state within the aerogel matrix, with traces of residual crystallinity. SEM observations revealed reduced pore size and increased matrix density following urea loading, indicating a more compact internal structure favorable for sustained release. CMC-GE aerogels crosslinked with GA are promising controlled-release carriers for urea. The optimized 1:3 CMC:GE aerogel demonstrated enhanced swelling and significantly slower urea release than xerogels and medical-grade urea, highlighting its potential for sustained urea delivery.
Indexed as
Identifiers
42711488What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.